Drug Profile
Research programme: respiratory tract disorder therapeutics - Ockham Biotech
Alternative Names: DNase/heparin; Endonucleases - Ockham Biotech; Heparin/DNaseLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ockham Biotech
- Class Endodeoxyribonucleases; Heparins
- Mechanism of Action Deoxyribonuclease 1 stimulants; Endonuclease stimulants; Enzyme replacements; Nucleic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in United Kingdom (Inhalation)